TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Theratechnologies · Lipodystrophy · HIV Infections
Phase 3
Completed
263
2022-09
Industry sponsor intelligence
TheratechnologiesClinical Pipeline.
Lead-sponsor view of Theratechnologies's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 7
- Recruiting
- 0
- Active
- 0
- Completed
- 4
- Results posted
- 2
- Avg enrollment
- 147
Pipeline overview
Programs by phase and activity.
Velocity
Theratechnologies trials by start year
Study start year · indexed snapshot
Development
Trials by phase
6phase labels
Early Phase 10
Phase 11
Phase 22
Phase 32
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Tesamorelin → | 7 | 1 | 2 | 2 | 1 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Theratechnologies · HIV
Phase 1
Completed
18
2013-12
TH9507 in Patients With HIV-Associated Lipodystrophy
Theratechnologies · HIV Infections · Lipodystrophy
Phase 3
Completed
412
2013-11
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Theratechnologies · Type 2 Diabetes
Phase 2
Completed
55
2010-12
Search sponsor records
All Theratechnologies studies.
This page groups studies where Theratechnologies is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
7 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT00608023TH9507 Extension Study in Patients With HIV-Associated LipodystrophySep 30, 2022NCT01388920Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingMar 18, 2022NCT01579695Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®Sep 11, 2018NCT01591902Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®Sep 11, 2018NCT02012556Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive PatientsDec 16, 2013NCT00123253TH9507 in Patients With HIV-Associated LipodystrophyNov 27, 2013NCT01264497Safety Study of TH9507 in Subjects With Stable, Type 2 DiabetesDec 21, 2010